Domestic CAR-T therapy listed the second! After raising $100 million in the round of the drug- and financial giant noir B-round, or list hong Kong stocks. The doctor was bombarded with explosives.

Nearly 100 authoritative leaders of domestic bio innovative drugs have spoken, hundreds of leading Biopharmaceutical Enterprises have paid close attention to it. More than 1000 pharmaceutical peers have signed up to participate. Dozens of innovative drug technologies have been collectively unveiled. Four hot biomedical fields, including tumor immunity, new antibodies, stem cell regenerative medicine, and gene therapy, are focused on. 2020 bpit The biopharmaceutical innovation technology conference will be held in Nanjing International Youth Cultural Center. From July 19 to 21, 2020, we will pay tribute to the next golden decade of innovative drugs and witness the new goals and new mileage of Chinese innovative drugs! This article is originally created by Medilac, welcome to share, and reprint must be authorized July 1, 2020 / emedclub news / - - yesterday, according to the CDE official website, the drug mingjunuo car-t cell therapy drug ruijilenzai was applied for listing.this is the second car-t cell therapy to be listed in China after Fosun KITT.} image source: CDE official website, myjuno is an innovative biotechnology company focusing on the clinical stage of the latest cell therapy technology field, which was jointly founded by Wuxi Kant group and Juno company in the United States in 2016.based on jcar017 of Juno company in the United States, ruijilansai (R & D Code: jwcar029) is a car-t cell therapy for relapsed and refractory lymphoma and leukemia, which is independently developed by medicino on the basis of jcar017 of Juno company.recommended reading: cell immunotherapy plus code! At the 61st annual meeting of the American Society of Hematology (ash) held in December last year, imipenem announced that jwcar029 was the first approved clinical CD19 targeted car-t product in China. Shanghai yaojunuo biotechnology completed a round of financing of 90 million US dollars/ Data from a single arm, open, incremental phase I clinical trial of refractory B-cell non Hodgkin's lymphoma (R / R B-NHL).the data showed that jwcar029 showed good safety and efficacy in a phase 1 study of 32 patients and 4 climbing doses.for poor prognosis patients with R / R invasive B-NHL, infusion of jwcar029 can achieve excellent and lasting remission. At 6 months, the orr of all patients (n = 29) was 58.6%, and the CR rate was 55.2%; for DLBCL patients with all reinfusion doses, Orr was 45%, CR rate was 45%.in terms of safety, jwcar029 toxicity was controllable, no CRS or NT related deaths occurred, and the incidence of grade 3 / 4 CRS or NT was low, about 6% (n = 32).} clinical data sheet of jwcar029. Nowadays, Juno has started to start the commercial layout of jwcar029 and promote the industrialization process of jwcar029.at the beginning of this month, yaomingjunuo announced the completion of US $100 million round B financing.this round of investment is led by CPE and future assets, followed by China Resources Zhengda life science fund and Yuanhe holding company, and the original investors zhengxingu innovation capital, Temasek, Sequoia Capital China fund, arch venture partners, junuo medical, and yaomingkant continue to support the investment.up to now, the total financing amount of the company has reached 200 million US dollars.in addition, it has been disclosed in the first two months that yaomingjunuo plans to complete the listing of Hong Kong shares this year, with a capital raising scale of US $200 million to US $300 million, and has appointed Goldman Sachs and UBS to arrange the listing.in view of the recent dynamic layout of mingjunuo, this year's car-t industry event: not long ago, Nanjing legend bio landed on the US NASDAQ capital market, and its share price rose by 60.8% on the first day of listing, and its total market value soared to nearly 4.8 billion US dollars, becoming the first share of car-t in China.according to the prospectus, legend is making every effort to promote the global clinical trial of lcar-b38m / jnj-4528, a car-t drug with rapid commercialization, and plans to submit an application for the license of jnj-4528 for the treatment of multiple myeloma to FDA in the second half of 2020.in February this year, Fosun KITT announced that the company's first car-t drug fkc876 (yijiliansai injection (proposed)) was officially accepted by the State Drug Administration, becoming the first car-t cell therapy to be listed in China. At present, the company is also actively working on the commercial layout of the treatment.it can be seen that car-t cell therapy in China has entered the countdown to the market, and the field will soon enter the stage of commercial competition. in this regard, emamect will launch bpit in 2020 At the third tumor immunotherapy technology seminar of biopharmaceutical innovation technology conference, many big men in car-t industry were invited to bring all aspects of industry analysis for everyone, and the industry report compiled by medico was published. All interested partners are welcome to participate in the seminar and exchange and study with you! Focusing on four popular biomedical fields, including tumor immunity, new antibodies, stem cell regenerative medicine and gene therapy, the 2020 bpit biopharmaceutical innovation technology conference will be held in Nanjing International Youth Culture Center, China, on July 19-21, 2020! Click the picture above to view the agenda of the conference